Source: Ayurcann Marketplace
  • Ayurcann Holdings (AYUR) has closed a non-brokered private placement for gross proceeds of $1,387,863.72
  • The company issued 7,710,354 units, priced at $0.18 per unit
  • Finders received $17,747.28 in cash and 98,594 broker warrants
  • Ayurcann has granted 1,253,125 restricted share units to certain directors, officers, employees and consultants
  • Ayurcann Holdings is a provider of customized post-harvest outsourcing solutions to licensed cannabis producers
  • Ayurcann Holdings Corp. (AYUR) opened trading at C$0.20 per share

Ayurcann Holdings (AYUR) has closed a non-brokered private placement for gross proceeds of $1,387,863.72.

The company issued 7,710,354 units, priced at $0.18 per unit. 

Each unit consists of one common share and one purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.22 for a period of three years from the date of the closing of the offering.

The warrants are subject to an acceleration provision.

Finders received $17,747.28 in cash and 98,594 broker warrants. 

Net proceeds of the offering will be used for general working capital.

Ayurcann has granted 1,253,125 restricted share units to certain directors, officers, employees and consultants. All restricted share units vest immediately.

Ayurcann is focused on becoming the partner of choice for Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

Ayurcann Holdings Corp. (AYUR) opened trading at C$0.20 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.